Storing and Disposing of a Weekly Injectable at Home in India

You were handed a device, possibly shown how to use it, and then sent home with the parts nobody explains: where to keep it, what to do when the power goes off for four hours in May, and where the used needle is supposed to go.

Two answers run through everything below. On storage, only the leaflet inside your own carton governs, because the allowances outside the refrigerator differ sharply between presentations and are not interchangeable. On the needle, Indian law already has a position, and as of 2026 it is clearer than older Indian articles suggest: a used sharp from home care is a regulated waste stream, not household rubbish.

Key Takeaways:

• Read only the leaflet inside your own carton for out-of-fridge windows. The allowances differ between molecules and presentations and cannot be borrowed from another drug or another person's pen.
• Never freeze any device in this class. Freezing damages the medicine, and the damage is invisible to inspection.
• A power cut does not automatically spoil the device. Write down when the cut started and the highest temperature reached, then check against your carton's temperature range when power returns.
• A used needle is regulated clinical waste under India's Bio-Medical Waste Management Rules 2016. It must go into a puncture-resistant container, not into household rubbish or a recycling bin.
• A device is never shared between patients and a needle is never reused by the same patient. Both are clinical safety rules, not hygiene preferences.

Most weekly injectables in this class are labelled for refrigerated storage at 2 to 8°C before first use, protected from light and never frozen, whether the molecule is semaglutide, tirzepatide, dulaglutide or prolonged-release exenatide. That much is common ground. What is not common ground is the allowance each presentation receives outside the refrigerator, and that is where readers most often assume their device behaves like a friend's.

The approved product information for these presentations sets out the following. The figures sit a long way apart:

Labelled out-of-fridge allowances by presentation:

• Semaglutide, single-dose weight-management pen: Up to 28 days at 8–30°C before the cap is removed. Discard after exposure above 30°C, freezing or light.
• Semaglutide, multi-dose weight-management pen (FlexTouch): Six weeks after first use, below 30°C or refrigerated, with the cap on for light protection.
• Semaglutide, multi-dose pen (diabetes presentation): 56 days after first use at 15–30°C or 2–8°C, kept capped and away from excessive heat and sunlight.
• Tirzepatide, single-dose pen or vial: Up to 21 days away from refrigeration, not above 30°C, kept in the original carton.
• Tirzepatide, multi-dose pen (KwikPen): Below 30°C for up to 30 days after first use.
• Dulaglutide, single-dose device: Up to 14 days, not above 30°C, protected from light.
• Exenatide, prolonged-release single-dose device: Up to four weeks, not above 30°C, stored flat and in the original package.

Three things follow from this:

1. The in-use period is a period, not a quantity. Discard the device at the end of the labelled in-use period even if liquid remains in it.
2. Write the date on the carton when the product first leaves the refrigerator, or when a multi-dose device is first used. None of these windows can be reconstructed from memory.
3. Do not combine or restart separate room-temperature periods unless your exact leaflet permits it.

Two caveats belong here rather than buried after the list. India's expert committee has recommended approval of updated package information for the semaglutide weight-management presentations, aligned with a European summary of product characteristics dated December 2025, so presentation-specific leaflets can and do change. And several of the label documents above are old enough to have been superseded.

That is one more reason the carton in your hand outranks any table, including this one.

Keep the product in its carton on a central refrigerator shelf, away from the freezer plate, the cooling outlet and food spills. Do not store it loose in the door, where the temperature swings every time someone reaches for water. A small refrigerator thermometer tells you more than the control dial does. The dial reports an intention, the thermometer reports a result.

During a power cut, keep the door shut and write down the time it started and the highest temperature you know the compartment reached. That record is what makes the next conversation with your pharmacist or clinician useful.

Indian outdoor conditions can run far above the 30°C ceiling that appears on most of these labels. The India Meteorological Department reported maximum temperatures of 43 to 47°C across large areas in May 2026. A pen left in a parked vehicle, on a windowsill or in a bag in that heat is outside every window listed above.

For travel, the task is to hold the product inside its own labelled range rather than to make it as cold as possible. An insulated medicine pouch does that. A cool bag packed with frozen gel packs in direct contact with the device does the opposite, because freezing is a disposal event for these products, not a storage method.

Carry it in cabin or personal baggage with the labelled carton, the prescription and, ideally, a short letter from your doctor. Air India's published guidance permits essential prescription medicines and medically necessary ice subject to screening and documentary proof, while stating that refrigeration aboard is not available. The cooling you bring is the cooling you have.

No equivalent medicine-specific cold-chain protocol for Indian Railways was located. Rail passengers should plan and monitor their own temperature control and should not assume anything onboard will do it for them.

Heat, freezing, light and mechanical stress can alter peptide conformation or drive chemical degradation and aggregation. The extent depends on the molecule, the formulation, the duration and the temperature. The labels for both semaglutide and tirzepatide state that a device that has frozen must not be used, whatever it looks like afterwards.

Cloudiness, a colour change or visible particles are reasons to reject a device. Normal appearance is not a reason to trust one. Visual inspection detects visible defects. It cannot detect molecular change, loss of potency or loss of sterility.

The useful response to an uncertain excursion is procedural:

• Set the device aside and record the approximate duration and temperature.
• Ask the manufacturer's medical-information service or your dispensing pharmacist for a product-specific stability assessment.
• Do not shake it, do not "test" it, and do not compensate by altering what was prescribed.

Whether a pack is genuine in the first place is a separate question from whether it has been stored properly.

Part 2, paragraph 12 of Schedule I to the Bio-Medical Waste Management Rules 2016, as subsequently amended, states that biomedical waste generated during household healthcare must be segregated and handed over separately to municipal waste collectors. Schedule I places contaminated metal sharps in the white, translucent stream and requires a container that is puncture-proof, leak-proof and tamper-proof.

The Solid Waste Management Rules 2026, effective from 1 April 2026, define household needles and syringes as "special care waste". Rule 5 places a duty on the household generator to keep that stream separate and hand it to an authorised waste picker or collector.

In practice, that means four things:

• Put each detached needle straight into a closable sharps container: Keep the container upright and out of reach of children. Never put a loose sharp into wet, dry or recyclable waste.
• Avoid improvising: Do not bend, break or hand-cut a needle. A purpose-built cutter or destroyer is an option, not a licence to manipulate a needle by hand.
• Ask your municipality which authorised collector or special-care-waste point accepts the sealed container. No nationwide mandatory pharmacy take-back scheme for self-care sharps was located.
• Treat a device with an integral needle as a sharp in its own right: Put it in the sharps container. Where the needle detaches, follow the device leaflet and the collector's instructions for the needle-free body.

Two gaps are real and worth knowing about. The Rules create a segregation duty and a handover duty, but no patient-facing national collection map or uniform handover procedure, so the last step genuinely depends on your local authority. A 2025 CAG audit found no source segregation of household biomedical waste in any test-checked urban local body, despite the collection duty existing on paper. That is a service-delivery failure, not permission to put sharps into ordinary rubbish. Seal the container properly and find out who in your city is authorised to take it.

The people downstream of that decision have been studied. A 2013 Kerala study of 313 municipal waste workers found that 73.2% reported a sharps injury at some point since entering the job and 5.1% within the preceding month, and that 70% handled waste containing sharps. A 2016 survey of 160 waste loaders in one Mumbai ward reported frequent lacerations attributed to needles and glass.

What follows from a percutaneous exposure to infected blood is well characterised: hepatitis B, hepatitis C and HIV can all be transmitted this way, with the risk varying by pathogen, the nature of the injury and vaccination status.

A loose needle in a bin bag is not an untidy habit. It is a specific hazard transferred to a named group of workers who did not choose it and cannot see it coming.

Never share a device, even after changing the needle. Blood can contaminate the device itself, which creates a blood-borne-pathogen risk that a fresh needle does not remove. Use a new needle each time, reuse is associated with blockage, contamination and tissue trauma.

Repeated injection into one area is associated with lipohypertrophy, a lumpy thickening of tissue that can make absorption delayed and unpredictable. If you notice a lump, a thickened patch or a local reaction that does not settle, the person to show it to is your prescriber, who can examine it and decide what it means.

Before a first self-administered dose, the prescriber, nurse or pharmacist should:

• Identify the exact device you have been given and provide its current instructions for use.
• Demonstrate both preparation and disposal, and watch you handle it.
• Explain the storage limits that apply to that presentation.
• Supply or identify a sharps container and name the local return route.

This is not an aspirational list. The approved information for tirzepatide explicitly requires presentation-specific training, and the semaglutide information states that a healthcare professional should demonstrate first use.

If nobody demonstrated your device, nobody gave you or pointed you to a sharps container, and nobody named a return route, you were short-changed. Ask for a device-specific session with a clinician or pharmacist.

Questions about how to store, use, or dispose of your injectable correctly? Speak to a Voy clinician; a quick review beats guessing.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.